

# IMPORTANT SASKATCHEWAN HEALTH PROGRAM INFORMATION DEXCOM G6 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM

Effective June 1, 2021, the Dexcom G6 Continuous Glucose Monitoring (CGM) System has been approved for coverage by Saskatchewan Health for pediatric patients under the age of 18.

## How do patients qualify?

To receive coverage for Dexcom G6 under the Saskatchewan Drug Plan, patients must be:

- Under the age of 18, **and**
- On intensive insulin therapy, **and**
- Eligible under the provincial requirements, **and**

For a complete description of provincial requirements, please visit:

<https://formulary.drugplan.ehealthsask.ca/EDStProg>

## What are the next steps for the patient?

If a patient believes they meet criteria above, they should contact their diabetes care team. The diabetes team will review each request to determine eligibility, and follow-up with them once the request has been processed.

## How do approved patients get Dexcom products?

If approved, the diabetes team will provide a written prescription or send the prescription directly to the patient's pharmacy of choice. Patients can then go their local pharmacy for fulfillment, or contact Dexcom to order their Dexcom supplies directly. The choice is theirs.

## How long will patients be covered for?

Once approved, initial coverage for the Dexcom G6 CGM System is valid for **one year**. Coverage is renewed every year until such time that the patient is 18 years of age.

## What if a patient has private insurance?

If the patient is approved for coverage through Saskatchewan Health, they will be covered **in full** and their Dexcom CGM supplies will be billed directly to Saskatchewan Health by their pharmacy or Dexcom. Coverage through Saskatchewan Health will stop when the patient is age 18, at which time we recommend they contact their insurance provider to inquire about coverage moving forward.

If a patient is not approved for coverage by Saskatchewan Health, they may submit invoices for Dexcom CGM supplies to their private insurance provider if they have coverage and are authorized to do so.

## Who do I contact if I have questions?

**Healthcare professionals** can find helpful information, resources and videos online at [ca.provider.dexcom.com](https://ca.provider.dexcom.com), or may contact us by toll-free phone at 1-844-536-8388 or by email at [ca.hcpsales@dexcom.com](mailto:ca.hcpsales@dexcom.com).

**Patients** can find helpful information, resources and videos online at [Dexcom.com](https://Dexcom.com), or may contact us by toll-free phone at 1-844-832-1810 or by email at [ca.sales@dexcom.com](mailto:ca.sales@dexcom.com).

# THE POWER TO CHANGE HOW PATIENTS LIVE WITH DIABETES

## Dexcom G6



Dexcom G6 measures glucose levels up to every five minutes using a sensor inserted just underneath the skin, and wirelessly transmits glucose readings to a receiver or compatible smart device.‡



### Zero fingersticks\* or scanning required

No fingersticks\* needed for treatment decisions or insulin dosing



### Custom alerts and alarm

Customizable high and low glucose alerts, and an Urgent Low Soon alert that can proactively warn users if they will be  $\leq 3.1$  mmol/L within 20 minutes.



### Remote data sharing†

Capability to share glucose data with up to five loved ones



### 10-day sensor wear

New, extended 10-day sensor wear



### Dexcom CGM Lowers A1C<sup>1,5</sup>

Proven to reduce A1C and decrease risk of hypoglycemia for people using insulin<sup>1,3</sup>



### Reduces hypoglycemic events<sup>2,3</sup>

Demonstrated to reduce the number of hypoglycemic events in people with diabetes



### Increases time spent in range<sup>1,3</sup>

Dexcom CGM users spend more time in range than those using fingersticks



### Pediatrics

The only CGM approved for ages 2 years and up

For more info on Dexcom G6, visit us online:

## CA.PROVIDER.DEXCOM.COM

\* If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

† Internet connectivity required for data sharing. Following requires the use of the Follow App.

‡ For a list of compatible devices, visit [www.dexcom.com/compatibility](http://www.dexcom.com/compatibility).

1 Beck R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Injections for Insulin Delivery: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.

2 Heinemann L, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. The Lancet. 2018;391(10128): 1367-1377.

3 Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3).